REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress

Date : 10/17/2019 @ 11:00AM
Source : PR Newswire (US)
Stock : REGENXBIO Inc (RGNX)
Quote : 45.14  -1.72 (-3.67%) @ 10:59PM
REGENXBIO share price Chart
After Hours
Last Trade
Last $ 45.14 ◊ 0.00 (0.00%)

REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress

REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart

6 Months : From Jul 2019 to Jan 2020

Click Here for more REGENXBIO Charts.

ROCKVILLE, Md., Oct. 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of two posters at the European Society of Gene & Cell Therapy (ESGCT) 27th Annual Congress in Barcelona, Spain, taking place from October 22 to 25, 2019.

The data will be presented as follows:

Abstract Title: Characterization of a Novel AAV Capsid with Enhanced Brain Transduction Following Systemic Delivery (poster #P011)
Presenter: Subha Karumuthil-Melethil, Ph.D., Senior Scientist, Target Discovery, REGENXBIO
Session Title: Poster Session I
Date/Time: Wednesday, October 23, 2019, 1:00 p.m. to 3:00 p.m. CEST
Location: Multipurpose Hall P011

Abstract Title: AAV9.hCLN2 (RGX-181) Improves Survival and Neuropathology in TPP1m1J Mice, a Model for CLN2 Batten Disease (poster #P018)
Presenter: Nicholas Buss, Ph.D., Director, Preclinical Development, REGENXBIO
Session Title: Poster Session II
Date/Time: Thursday, October 24, 2019, 1:15 p.m. to 2:45 p.m. CEST
Location: Multipurpose Hall P018

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas. For more information, visit http://www.regenxbio.com.

Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

 

(PRNewsfoto/REGENXBIO Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-european-society-of-gene--cell-therapy-27th-annual-congress-300940114.html

SOURCE REGENXBIO Inc.

Copyright 2019 PR Newswire

Latest RGNX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200124 00:10:17